Potassium Channel News and Research

RSS

Intrinsically disordered protein responsible for inactivating BK channel

Tiny pores, or channels, embedded in cell membranes are critical to the healthy functioning of cells. Charged atoms, or ions, move through these channels to generate the electrical signals that allow cells to communicate with one another.

23 Apr 2012

Positive data from XENTION's XEN-D0103 phase 1 trial on AF

XENTION LTD, the Cambridge-based biopharmaceutical company specialising in the discovery and development of ion channel-modulating drugs, reported positive data today from a phase 1 trial of XEN-D0103 administered orally.

20 Mar 2012

Acorda's fourth quarter GAAP net income increases to $12.7 million

Acorda Therapeutics, Inc. today announced its financial results for the fourth quarter and full year ended December 31, 2011.

16 Feb 2012

BPS Annual Meeting to be held Feb. 25 - 29 in San Diego

The latest news and discoveries in medicine, physics, environmental science, and interdisciplinary fields will be featured at the 56th Annual Meeting of the Biophysical Society (BPS), held Feb. 25 - Feb. 29, 2012, at the San Diego Convention Center in San Diego, Calif. With more than 4,000 poster presentations, 200 exhibits, 20 symposia, and 6,000 research scientists in attendance each year, the BPS Annual Meeting is the largest meeting of biophysicists in the world.

7 Feb 2012

Increased sensitivity to low frequency vibration found in people with inherited hearing loss

People with a certain form of inherited hearing loss have increased sensitivity to low frequency vibration, according to a study by Professor Thomas Jentsch of the Leibniz-Institut f-r Molekulare Pharmakologie (FMP)/Max Delbr-ck Center for Molecular Medicine (MDC) Berlin-Buch and Professor Gary Lewin (MDC), conducted in cooperation with clinicians from Madrid, Spain and Nijmegen, the Netherlands.

9 Dec 2011

ABCC9 gene also influences duration of sleep in humans

A collaborative European study led by LMU researchers has shown that ABCC9, a known genetic factor in heart disease and diabetes, also influences the duration of sleep in humans.

24 Nov 2011

Brain plays a key role in regulating glucose metabolism in humans

Researchers at Albert Einstein College of Medicine of Yeshiva University have demonstrated for the first time that the brain is a key player in regulating glucose (sugar) metabolism in humans.

7 Nov 2011

Gilead, CRF commence ranolazine Phase 3 clinical trial for chronic stable angina in post-PCI setting

Gilead Sciences, Inc. and the Cardiovascular Research Foundation (CRF) today announced the initiation of RIVER-PCI (Ranolazine for Incomplete VEssel Revascularization post-PCI), a Phase 3 clinical trial evaluating the utility of ranolazine to prevent major adverse cardiovascular events (MACE) in patients with a history of chronic angina who have incomplete revascularization following percutaneous coronary intervention (PCI).

7 Nov 2011

Acorda third quarter GAAP net income increases to $18.9 million

Acorda Therapeutics, Inc. today announced its financial results for the third quarter ended September 30, 2011.

4 Nov 2011

Researchers uncover molecular pathway critical to cardiac arrhythmia

University of Maryland School of Medicine researchers have uncovered a previously unknown molecular pathway that is critical to understanding cardiac arrhythmia and other heart muscle problems.

27 Oct 2011

Molecular Endocrinology journal publishes two studies on estrogen hormones

University of Houston (UH) researchers have their sights set on developing possible treatments for breast and colon cancer.

23 Aug 2011

Acorda Therapeutics receives U.S. patent allowance for aminopyridine compositions

Acorda Therapeutics, Inc. today announced that the United States Patent and Trademark Office (USPTO) has allowed U.S. Patent Application No. 11/102,559 entitled "Method of Using Sustained Release Aminopyridine Compositions."

10 Aug 2011

Myelin regulates key protein involved in sending long-distance signals

The development of a new cell-culture system that mimics how specific nerve cell fibers in the brain become coated with protective myelin opens up new avenues of research about multiple sclerosis. Initial findings suggest that myelin regulates a key protein involved in sending long-distance signals.

22 Jul 2011

Acorda to move corporate headquarters to Ardsley Park life science campus

Acorda Therapeutics, Inc. today announced that it plans to relocate its corporate headquarters to the Ardsley Park life science campus in Ardsley, New York, which was acquired by BioMed Realty Trust, Inc..

27 Jun 2011

ABA honors Acorda Therapeutics president with 2011 Stevie Award

Acorda Therapeutics, Inc. announced that Ron Cohen, M.D., President and CEO of Acorda Therapeutics, was awarded the 2011 Stevie Award for Executive of the Year in the Health Products & Services category at the 9th Annual American Business Awards (ABA) ceremony held on June 20, 2011.

24 Jun 2011

FDA approves Valeant's Potiga Tablets for treatment of partial-onset seizures

Valeant Pharmaceuticals International, Inc. and GlaxoSmithKline announced today that the U.S. Food and Drug Administration (FDA) has approved Potiga Tablets, a potassium channel opener, as adjunctive treatment of partial-onset seizures in patients aged 18 years and older.

13 Jun 2011

Valeant Pharmaceuticals receives FDA approval for Potiga

Valeant Pharmaceuticals International Inc. has received approval from the U.S. Food and Drug Administration (FDA) for Potiga.

13 Jun 2011

AMPYRA ER Tablets improve walking ability in patients with multiple sclerosis

Acorda Therapeutics, Inc. today announced an analysis of pooled clinical trial results showed patients who were responders to AMPYRA (dalfampridine) Extended Release Tablets, 10 mg demonstrated clinically relevant improvements in walking ability as measured by patient self-report on the 12-Item Multiple Sclerosis Walking Scale (MSWS-12), regardless of either their baseline Expanded Disability Status Scale (EDSS) score or baseline walking speed.

7 Jun 2011

New research aims to improve treatment of diabetes and cardiovascular diseases

New research at the University of Leicester to contribute to more effective drug design. A cutting-edge research project at the University of Leicester is aiming to improve the treatment of diabetes and cardiovascular diseases.

3 Jun 2011

EMA CHMP recommends conditional marketing authorization of FAMPYRA

The Committee for Medicinal Products for Human Use of the European Medicine Agency has recommended conditional marketing authorization of FAMPYRA (prolonged-release fampridine 10 mg tablets) for the improvement of walking in adult patients with multiple sclerosis with walking disability.

20 May 2011